Vera Therapeutics (NASDAQ:VERA) said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or ...

Novartis Pharmaceuticals Canada Inc. ("Novartis Canada") announced today that Health Canada has granted approval for VANRAFIATM (atrasentan tablets) for proteinuria reduction in adults with primary ...

When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...

Trutakna, priced at $425,000 per year, is the first drug approved in the U.S. that targets both BAFF and APRIL proteins ...

It has not been established whether atacicept slows kidney function decline long-term, how ...

Data from the first stage of a phase 3 study show significant reductions in proteinuria among patients treated with telitacicept.

The FDA approved a new medicine from the biotech company Vera Therapeutics for patients with a type of chronic autoimmune ...

Medically reviewed by Matthew Wosnitzer, MD Key Takeaways IgA nephropathy is diagnosed through a combination of clinical findings, urine and blood tests, and a renal (kidney) biopsy.IgA nephropathy ...

Diabetic nephropathy is a common complication associated with diabetes that affects a person’s kidneys. Several medications may help slow the progression of kidney damage. Early treatment can prevent ...

WITH THE INCREASING USE OF CONTRAST MEDIA in diagnostic and interventional procedures, nephropathy induced by contrast media has become the third leading cause of hospital-acquired acute renal failure ...

Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position. William Turner, current Chief ...

ORIGIN 3 randomized 431 biopsy‑confirmed IgAN patients 1:1; atacicept 150 mg weekly SC produced the largest placebo‑adjusted UPCR reduction reported at week 36. Accelerated approval hinged on ...